Baseline characteristics, cardiovascular disease, and all-cause mortality according to genotype
| . | Without mutations (n = 82) . | JAK2 V617F (n = 7) . | P . | BCOR/BCORL1 (n = 20) . | P . | Other mutations (n = 24) . | P . |
|---|---|---|---|---|---|---|---|
| Male/female, % | 30.5/69.5 | 42.9/57.1 | .50 | 30.0/70.0 | .97 | 16.7/83.3 | .18 |
| Age, y | 48.4 ± 10.3 | 61.3 ± 10.4 | .002 | 53.4 ± 12.4 | .066 | 53.3 ± 8.2 | .033 |
| Hb, g/dL | |||||||
| Male | 18.5 ± 2.3 | 17.8 ± 0.7 | .18 | 17.8 ± 0.6 | .88 | 18.4 ± 0.9 | .12 |
| Female | 16.2 ± 0.4 | 16.2 ± 0.4 | .86 | 16.3 ± 0.8 | .57 | 16.1 ± 0.5 | .35 |
| Hct, % | |||||||
| Male | 52.8 ± 0.7 | 57.5 ± 9.0 | .007 | 52.8 ± 0.7 | .85 | 53.3 ± 0.1 | .20 |
| Female | 49.1 ± 2.1 | 49.6 ± 1.4 | .64 | 48.8 ± 0.7 | .62 | 48.9 ± 1.1 | .81 |
| MCV, fL | 93.5 ± 4.3 | 89.3 ± 4.7 | .016 | 93.2 ± 4.0 | .79 | 92.7 ± 4.1 | .42 |
| Leukocytes, ×109/L | 8.6 ± 2.7 | 9.8 ± 3.0 | .28 | 7.9 ± 2.4 | .29 | 8.3 ± 2.7 | .54 |
| % Leukocytosis | 29.3 | 4/7 (57.1%) | .31 | 25.0 | .81 | 25.0 | .61 |
| Platelets, ×109/L | 270 ± 62 | 524 ± 180 | <.001 | 242 ± 60 | .07 | 254 ± 54 | .25 |
| % Thrombocytosis | 4.9 | 5/7 (71.4%) | <.001 | 0.0 | .34 | 0.0 | .46 |
| Composite cardiovascular events, % | 4.9 | 2/7 (28.6%) | .016 | 15.0 | .11 | 12.5 | .19 |
| All-cause mortality, % | 4.9 | 1/7 (14.3%) | .30 | 10.0 | .38 | 4.2 | .89 |
| . | Without mutations (n = 82) . | JAK2 V617F (n = 7) . | P . | BCOR/BCORL1 (n = 20) . | P . | Other mutations (n = 24) . | P . |
|---|---|---|---|---|---|---|---|
| Male/female, % | 30.5/69.5 | 42.9/57.1 | .50 | 30.0/70.0 | .97 | 16.7/83.3 | .18 |
| Age, y | 48.4 ± 10.3 | 61.3 ± 10.4 | .002 | 53.4 ± 12.4 | .066 | 53.3 ± 8.2 | .033 |
| Hb, g/dL | |||||||
| Male | 18.5 ± 2.3 | 17.8 ± 0.7 | .18 | 17.8 ± 0.6 | .88 | 18.4 ± 0.9 | .12 |
| Female | 16.2 ± 0.4 | 16.2 ± 0.4 | .86 | 16.3 ± 0.8 | .57 | 16.1 ± 0.5 | .35 |
| Hct, % | |||||||
| Male | 52.8 ± 0.7 | 57.5 ± 9.0 | .007 | 52.8 ± 0.7 | .85 | 53.3 ± 0.1 | .20 |
| Female | 49.1 ± 2.1 | 49.6 ± 1.4 | .64 | 48.8 ± 0.7 | .62 | 48.9 ± 1.1 | .81 |
| MCV, fL | 93.5 ± 4.3 | 89.3 ± 4.7 | .016 | 93.2 ± 4.0 | .79 | 92.7 ± 4.1 | .42 |
| Leukocytes, ×109/L | 8.6 ± 2.7 | 9.8 ± 3.0 | .28 | 7.9 ± 2.4 | .29 | 8.3 ± 2.7 | .54 |
| % Leukocytosis | 29.3 | 4/7 (57.1%) | .31 | 25.0 | .81 | 25.0 | .61 |
| Platelets, ×109/L | 270 ± 62 | 524 ± 180 | <.001 | 242 ± 60 | .07 | 254 ± 54 | .25 |
| % Thrombocytosis | 4.9 | 5/7 (71.4%) | <.001 | 0.0 | .34 | 0.0 | .46 |
| Composite cardiovascular events, % | 4.9 | 2/7 (28.6%) | .016 | 15.0 | .11 | 12.5 | .19 |
| All-cause mortality, % | 4.9 | 1/7 (14.3%) | .30 | 10.0 | .38 | 4.2 | .89 |
Data are given as mean ± standard deviation, median (interquartile range) when not normally distributed, or percentage. P values were calculated between individuals without mutations and the 3 genotypes. Leukocytosis was defined as leukocytes ≥10 × 109/L. Thrombocytosis was defined as a platelet count ≥400 × 109/L. The category of other mutations includes mutations in ASXL1, CALR, CSF3R, DNMT3A, EZH2, NRAS, RUNX1, SF3B1, TET2, and TP53.